<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05085977</url>
  </required_header>
  <id_info>
    <org_study_id>TARA-002-101 (Phase 1a)</org_study_id>
    <nct_id>NCT05085977</nct_id>
  </id_info>
  <brief_title>Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)</brief_title>
  <acronym>ADVANCED-1</acronym>
  <official_title>A Phase 1a/b Dose Finding, Open-label Study to Evaluate Safety and Toxicity of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Protara Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Protara Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open-label dose escalation study (Phase 1a) to investigate the safety and&#xD;
      toxicity of intravesical treatment of high-grade NMIBC (HGTa or CIS) after transurethral&#xD;
      resection of bladder tumor (TURBT) and/or biopsy using TARA-002 in adults unable to obtain&#xD;
      intravesical Bacillus Calmette-Guérin (BCG), adults who have received at least one dose of&#xD;
      intravesical BCG or adults who have received at least one dose of intravesical chemotherapy.&#xD;
      Dosing will start in subjects with HGTa or CIS NMIBC to include a minimum of 1 dosing cohort&#xD;
      and a maximum of 3 total dosing cohorts. All subjects will receive 6 weeks of treatment at a&#xD;
      fixed volume with varying doses levels.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Up to 3 dose levels of TARA-002 (10 KE → 20 KE → 40 KE) will be tested sequentially with 6 weekly intravesical doses starting with the lowest dose using a 3+3 design in a dose escalation manner</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1a, Dose Escalation Phase: Incidence of DLT AEs in subjects with HGTa or CIS NMIBC</measure>
    <time_frame>Day 1 to Day 43</time_frame>
    <description>DLT = dose limiting toxicities; HGTa = high grade Ta; CIS = carcinoma in situ</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1a, Dose Escalation Phase: MTD and RP2D of TARA-002 in subjects with HGTa or CIS NMIBC</measure>
    <time_frame>Day 1 to Day 43</time_frame>
    <description>MTD = maximum tolerated dose; RP2D = recommended Phase 2 dose</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Non-muscle Invasive Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>TARA-002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TARA-002 is a lyophilized biological preparation for instillation containing cells of Streptococcus pyogenes (Group A, type 3) Su strain treated with benzylpenicillin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TARA-002</intervention_name>
    <description>Phase 1a, Dose Escalation: Up to 3 dose levels of TARA-002 (10 KE → 20 KE → 40 KE) will be tested sequentially with 6 weekly intravesical doses starting with the lowest dose using a 3+3 design in a dose escalation manner</description>
    <arm_group_label>TARA-002</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects 18 years of age or older at the time of signing the informed&#xD;
             consent&#xD;
&#xD;
          -  Subjects who have voluntarily given written informed consent after the nature of the&#xD;
             study has been explained according to applicable requirements prior to study entry&#xD;
&#xD;
          -  Subjects with a histologically confirmed, high-grade Ta or CIS urothelial cell&#xD;
             carcinoma of the bladder according to American Joint Committee on Cancer staging and&#xD;
             2016 WHO/ISUP grading classification.&#xD;
&#xD;
          -  Subjects who are unable to obtain intravesical BCG for the treatment of NMIBC, have&#xD;
             received at least one dose of intravesical BCG, or at least one dose of intravesical&#xD;
             chemotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Penicillin allergy (subjects with a questionable history of allergy to penicillin or&#xD;
             no history of penicillin use will undergo sensitivity testing prior to inclusion in&#xD;
             the study)&#xD;
&#xD;
          -  Predominant (defined as &gt; 50%) adenocarcinoma, squamous cell carcinoma, or&#xD;
             histological variants including plasmacytoid, sarcomatoid, or squamous components&#xD;
&#xD;
          -  Prostatic involvement, upper tract urothelial carcinoma, nodal involvement, or&#xD;
             metastatic disease&#xD;
&#xD;
          -  Bladder cancer stage ≥ T1 according to American Joint Committee on Cancer staging&#xD;
             criteria&#xD;
&#xD;
          -  Bladder cancer stage CIS with concomitant T1&#xD;
&#xD;
        For more information on eligibility criteria, please contact the sponsor.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Scientific Operations Officer</last_name>
    <role>Study Director</role>
    <affiliation>Protara Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chief Scientific Operations Officer</last_name>
    <phone>16468440337</phone>
    <email>clinicaltrials@protaratx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>New Jersey Urology</name>
      <address>
        <city>Mount Laurel</city>
        <state>New Jersey</state>
        <zip>08054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Use Central Contact</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 7, 2021</study_first_submitted>
  <study_first_submitted_qc>October 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-muscle invasive bladder cancer</keyword>
  <keyword>bladder cancer</keyword>
  <keyword>high grade Ta</keyword>
  <keyword>carcinoma in situ</keyword>
  <keyword>high-grade NMIBC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

